|Bid||0.00 x 800|
|Ask||0.00 x 2200|
|Day's Range||6.47 - 6.87|
|52 Week Range||1.20 - 6.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
TransEnterix (TRXC) acquires Israel-based MST Medical, which will boost surgeons' effectiveness and make procedures quick and error-free.
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / U.S. markets were mixed on Friday, with the Dow Jones managing to close at an all-time high despite a plunge in technology and internet stocks. The Dow Jones Industrial Average gained 0.32 percent to close at 26,743.50, while the S&P 500 Index declined 0.04 percent to close at 2,929.67.
TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced that it has acquired substantially all of the assets of MST Medical Surgery Technologies Ltd. (“MST”), an Israel medical technology company, in a cash and stock transaction with a total consideration, further described below. MST is a leader in the field of surgical technology, having developed a software-based image analytics platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics.
Investors are always looking for growth in small-cap stocks like TransEnterix Inc (NYSEMKT:TRXC), with a market cap of US$1.36b. However, an important fact which most ignore is: how financially healthyRead More...
Jim Cramer rattles off his take on callers' favorite stocks, including a streaming play that he's gotten wrong in the past.
The robotic surgery specialist posted another big month on nothing more substantial than a single, tight-lipped analyst action.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company filed a FDA 510(k) submission for its Senhance Ultrasonic Instrument System. Advanced energy devices, including ultrasonic devices, represent some of the most versatile and critical tools for surgeons in minimally invasive surgery. “Advanced energy devices are an important tool within laparoscopic surgery because of their applicability within a wide range of procedures,” said Todd M. Pope, TransEnterix CEO.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018. In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence. “We are very excited to have Eric join the TransEnterix team.
On August 24, TransEnterix (TRXC) stock closed at $5.37, which represents a ~6.13% growth from its prior day’s close of $5.06. On August 24, TransEnterix closed at $5.37, which is ~12% below its 52-week high of $6.04 on June 27. TransEnterix, a medical device company, is focused on the development of minimally invasive surgical devices with the digitalization of the interface between the surgeon and the patient.
TransEnterix (TRXC) expects to sell three Senhance systems in Q3 2018. While the company expects lower capital sales in the third quarter, it expects sales to be stronger in Q4 2018. Wall Street analysts have projected TransEnterix’s fiscal 2018 revenues to be around $24.7 million, which would be a YoY rise of approximately 248%.
In Q2 2018, TransEnterix (TRXC) sold four Senhance surgical robots. Senhance is approved in the US for multiple digital laparoscopic procedures such as an inguinal hernia, colorectal surgery, cholecystectomy surgery, and gynecologic surgery. TransEnterix aims to expand the penetration of surgical robotics globally, which currently stands under 10%.
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference at The Westin Copley Place in Boston, Massachusetts.
In its latest look at the financials of these publicly traded companies, Triangle Business Journal dove deeper into the data to see how these companies fall in the various regions of the state and how those areas stack up as of July 31, 2018 – and how these companies compare to last year.
Earnings season is in full swing, and companies are busy reporting their performance for the second quarter of the fiscal year. The same is true for Research Triangle Park’s biotech companies, BioDelivery Sciences (Nasdaq: BDSI), TransEnterix (Amex: TRXC) and Dova Pharmaceuticals (Nasdaq: DOVA) all announced their financial results during after-market hours in recent days.
TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017.
TransEnterix (NYSE: TRXC) is seeing its revenue climb on more sales following its initial U.S. Food and Drug Administration clearance late last year, although the company is still showing losses overall. On Tuesday, the Research Triangle Park-based surgical robot maker reported revenue of $6.4 million in the second quarter of 2018, compared to revenue of just $1.6 million in the second quarter of last year. TransEnterix reported a net loss of $34.2 million, or $0.17 per share, for the second quarter of 2018, compared to a net loss of $14.7 million, or $0.11 per share, for the second quarter of last year.
TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and 3.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Morrisville, North Carolina-based company said it had a loss of 17 cents per share. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of surgical robots ...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter 2018.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / TransEnterix, Inc. (NYSE American: TRXC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...